C-VWJZCircumvent Pharma
precision medicines, palmitoylome modulation, neurodegeneration
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-VWJZ
C-VWJZC-VWJZprecision medicines, palmitoylome modulation, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Circumvent Pharma precision medicines, palmitoylome modulation, neurodegeneration
Circumvent was formed to develop precision medicines for neurodegenerative disease, beginning with Batten Disease. The company focuses on diseases with predictive animal models, clear clinical development paths, and the potential to reach market quickly. Its work in Batten Disease has produced insights into brain-cell dysfunction, palmitoylation, the palmitoylome, and synaptic biology that it is applying across related neurological diseases.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Circumvent Pharma — Early mechanism · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic